

## Subject Index

**ADCC**, Herpes simplex virus, HSV glycoprotein, 279

**Acyclovir**, Herpes simplex virus, Guinea pig skin, Antitherapeutic substance, Pyrophosphate analogue, 99

**Acyclovir**, Microencapsulated anti-viral assay in mice, Herpes simplex virus, 179

**Adenovirus**, Herpes simplex virus, Cytomegalovirus, Retrovirus, Pyrrolopyrimidine nucleoside, 263

**Anti-HIV compound**, Chinese herb, Polysaccharide, Purification, Chromatography, Spectroscopy, 107

**Antitherapeutic substance**, Herpes simplex virus, Guinea pig skin, Pyrophosphate analogue, Acyclovir, 99

**Antiviral treatment**, Coxsackievirus, Lymphocyte subpopulation, Monoclonal antibody, Myocarditis, 129

**Bovine**, Tumor necrosis factor, Interferon, 71

**Castanospermine**, Cytomegalovirus, Glycoprotein complex, Inhibitor, glycoprotein processing enzyme, Deoxynojirimycin, 11

**Cephalosporin derivative**, DNA virus, 59

**Chinese herb**, Polysaccharide, Anti-HIV compound, Purification, Chromatography, Spectroscopy, 107

**Chromatography**, Chinese herb, Polysaccharide, Anti-HIV compound, Purification, Spectroscopy, 107

**Coxsackievirus**, Antiviral treatment, Lymphocyte subpopulation, Monoclonal antibody, Myocarditis, 129

**Cytomegalovirus**, Glycoprotein complex, Inhibitor, glycoprotein processing enzyme, Castanospermine, Deoxynojirimycin, 11

**Cytomegalovirus**, Herpes simplex virus, Adenovirus, Retrovirus, Pyrrolopyrimidine nucleoside, 263

**DNA synthesis**, 2'-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Incorporation, Metabolism, Selective inhibition, 153

**DNA virus**, Cephalosporin derivative, 59

**3-Deazauridine**, Immunofluorescence antiviral assay, Pichinde virus, Ribavirin derivative, (S)-9-(2,3-dihydroxypropyl)adenine, 89

**Deoxynojirimycin**, Cytomegalovirus, Glycoprotein complex, Inhibitor, glycoprotein processing enzyme, Castanospermine, 11

**(S)-9-(2,3-dihydroxypropyl)adenine**, Immunofluorescence antiviral assay, Pichinde virus, Ribavirin derivative, 3-Deazauridine, 89

**Enviroxime**, Synergy, Interferon a, Rhinovirus, Prophylaxis, 141

**2'-Fluoro-5-substituted-ara-pyrimidine**, herpes simplex virus, Incorporation, Metabolism, Selective inhibition, DNA synthesis, 153

**Genital wart**, Interferon alpha-1, Human papillomavirus, 41

**Glycoprotein complex**, Cytomegalovirus, Inhibitor, glycoprotein processing enzyme, Castanospermine, Deoxynojirimycin, 11

**Glycoprotein**, Immunotherapy, Recurrent genital herpes, 83

**Glycyrhizin**, Human immunodeficiency virus, Protein kinase C, Virus adsorption, 289

**Guinea pig skin**, Herpes simplex virus, Antitherapeutic substance, Pyrophosphate analogue, Acyclovir, 99

**(R,S)-HPMPG**, Herpesvirus, 235

**HSV glycoprotein**, Herpes simplex virus, ADCC, 279

**HSV-2 infection**, R-837, 209

**Herpes simplex virus**, 2'-Fluoro-5-substituted-ara-pyrimidine, Incorporation, Metabolism, Selective inhibition, DNA synthesis, 153

**Herpes simplex virus**, Microencapsulated anti-viral assay in mice, Acyclovir, 179

**Herpes simplex virus**, Cytomegalovirus, Adenovirus, Retrovirus, Pyrrolopyrimidine nucleoside, 263

**Herpes simplex virus**, ADCC, HSV glycoprotein, 279

**Herpes simplex virus**, OK-432, Immunomodulator, Immunosuppressed mice, 299

**Herpesvirus**, (R,S)-HPMPG, 235

**Human immunodeficiency virus**, Glycyrhizin, Protein kinase C, Virus adsorption, 289

**Human papillomavirus**, Interferon alpha-1, Genital wart, 41

**IFN- $\gamma$** , TNF, Potentiation, 1

**rIFN- $\alpha$ Con1**, Intranasal toxicity, 225

**Immunofluorescence antiviral assay**, Pichinde virus, Ribavirin derivative, 3-Deazauridine, (S)-9-(2,3-dihydroxypropyl)adenine, 89

**Immunomodulator**, OK-432, Herpes simplex virus, Immunosuppressed mice, 299

**Immunosuppressed mice**, OK-432, Immunomodulator, Herpes simplex virus, 299

**Immunotherapy**, Glycoprotein, Recurrent genital herpes, 83

**In vivo efficacy**, Murine cytomegalovirus, Interferon- $\gamma$ , Mortality prophylaxis, 27

**Incorporation**, 2'-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Metabolism, Selective inhibition, DNA synthesis, 153

**Inhibitor**, glycoprotein processing enzyme, Cytomegalovirus, Glycoprotein complex, Castanospermine, Deoxynojirimycin, 11

**Interferon- $\gamma$** , Murine cytomegalovirus, In vivo efficacy, Mortality, Prophylaxis, 27

**Interferon alpha-1b**, Genital wart, Human papillomavirus, 41

**Interferon**, Bovine, tumor necrosis factor, 71

**Interferon  $\alpha$** , Synergy, Enviroxime, Rhinovirus, Prophylaxis, 141

**Interferon-inducing activity**, Lipid A analog, Vaccinia virus, 167

**Intranasal toxicity**, rIFN- $\alpha$ Con1, 225

**Isoflavan**, Rhinovirus 1B, Isoflavene, 117

**Isoflavene**, Rhinovirus 1B, Isoflavan, 117

**Lipid A analog**, Vaccinia virus, Interferon-inducing activity, 167

**Lymphocyte subpopulation**, Coxsackievirus, Antiviral treatment, Monoclonal antibody, Myocarditis, 129

**Metabolism**, 2'-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Incorporation, Selective inhibition, DNA synthesis, 153

**Microencapsulated anti-viral assay in mice**, Herpes simplex virus, Acyclovir, 179

**Monoclonal antibody**, Coxsackievirus, Antivirus treatment, Lymphocyte subpopulation, Myocarditis, 129

**Mortality**, Murine cytomegalovirus, Interferon- $\gamma$ , In vivo efficacy, Prophylaxis, 27

**Murine cytomegalovirus**, Interferon- $\gamma$ , In vivo efficacy, Mortality, Prophylaxis, 27

**Myocarditis**, Coxsackievirus, Antiviral treatment, Lymphocyte subpopulation, Monoclonal antibody, 129

**OK-432**, Immunomodulator, Herpes simplex virus, Immunosuppressed mice, 299

**Phlebovirus**, Ribamidine, Punta Toro virus, Ribavirin, 193

**Pichinde virus**, Immunofluorescence antiviral assay, Ribavirin derivative, 3-Deazauridine, (S)-9-(2,3-dihydroxypropyl)adenine, 89

**Polysaccharide**, Chinese herb, Anti-HIV, compound, Purification, Chromatography, Spectroscopy, 107

**Potentiation**, TNF, IFN- $\gamma$ , 1

**Prophylaxis**, Murine cytomegalovirus, Interferon- $\gamma$ , In vivo efficacy, Mortality, 27

**Prophylaxis**, Synergy, Interferon  $\alpha$ , Enviroxime, Rhinovirus, 141

**Protein kinase C**, Glycrrhizin, Human immunodeficiency virus, Virus adsorption, 289

**Protein synthesis inhibition**, Ribavirin nucleotide analog, 253

**Punta Toro virus**, Ribamidine, Phlebovirus, Ribavirin, 193

**Purification**, Chinese herb, Polysaccharide, Anti-HIV compound, Chromatography, Spectroscopy, 107

**Pyrophosphate analogue**, Herpes simplex virus, Guinea pig skin, Antiherpetic substance, Acyclovir, 99

**Pyrrolopyrimidine nucleoside**, Herpes simplex virus, Cytomegalovirus, Adenovirus, Retrovirus, 263

**R-837**, HSV-2 infection, 209

**Recurrent genital herpes**, Glycoprotein, Immunotherapy, 83

**Retrovirus**, Herpes simplex virus, Cytomegalovirus, Adenovirus, Pyrrolopyrimidine nucleoside, 263

**Rhinovirus 1B**, Isoflavan, Isoflavene, 117

**Rhinovirus**, Synergy, Interferon  $\alpha$ , Enviroxime, Prophylaxis, 141

**Ribavirin derivative**, Immunofluorescence antiviral assay, Pichinde virus, 3-Deazauridine, (S)-9-(2,3-dihydroxypropyl)adenine, 89

**Ribavirin nucleotide analog**, Protein synthesis inhibition, 253

**Ribavirin**, Ribamidine, Phlebovirus, Punta Toro virus, 193

**Selective inhibition**, 2'-Fluoro-5-substituted-ara-pyrimidine, Herpes simplex virus, Incorporation, Metabolism, DNA synthesis, 153

**Spectroscopy**, Chinese herb, Polysaccharide, Anti-HIV compound, Purification, Chromatography, 107

**Synergy**, Interferon  $\alpha$ , Enviroxime, Rhinovirus, Prophylaxis, 141

**TNF**, IFN- $\gamma$ , Potentiation, 1

**Tumor necrosis factor**, Bovine, Interferon, 71

**Vaccinia virus**, Lipid A analog, Interferon-inducing activity, 167

**Virus adsorption**, Glycyrrhizin, Human immunodeficiency virus, Protein kinase C, 289

## Author Index

Al-Nakib, W., see Higgins, P.G., 141  
 Alaghmandan, H.A., see Smee, D.F., 253  
 Alaghmandan, H.A., see Smee, D.F., 263  
 Anderson, K.P., see Fennie, E.H., 27  
 Atchison, R.W., see Li, X.Q., 179

Baba, M., see Ito, M., 289  
 Babiu, L.A., see Campos, M., 71  
 Barnard, D.K., see Sidwell, R.W., 193  
 Barnett, B.B., see Burns, III, N.J., 89  
 Barrow, G.I., see Higgins, P.G., 141  
 Bernstein, D.I., Loo, L.S. and Kohl, S.  
 Antibody to cloned HSV glycoproteins B and  
 D plus adult human leukocytes protect neonatal mice from lethal HSV infection, 279  
 Bernstein, D.I., see Harrison, C.J., 209  
 Bernstein, D.I., see Myers, M.G., 83  
 Bielefeldt Ohmann, H., see Campos, M., 71  
 Bonnez, W., see Reichman, R.C., 41  
 Burns, III, N.J., Barnett, B.B., Huffman, J.H.,  
 Dawson, M.I., Sidwell, R.W., De Clercq, E.  
 and Kende M.  
 A newly developed immunofluorescent assay for  
 determining the Pichinde virus-inhibitory effects of selected nucleoside analogues, 89

Campos, M., Bielefeldt Ohmann, H., Hughes, G.,  
 Babiu, L.A. and Lawman, M.J.P.  
 Studies on the in vitro biological activities of recombinant bovine tumor necrosis factor (rBoTNF) alpha. I. Synergistic antiviral efficacy of rBoTNF alpha, recombinant bovine interferon gamma (rBoIFN gamma) and their combination, 71  
 Chang, R.S., see Ngan, F., 107  
 Chou, T.-C., see Kong, X.-B., 153  
 Conti, C., Orsi, N. and Stein, M.L.  
 Effect of isoflavans and isoflavones on rhinovirus 1B and its replication in HeLa cells, 117  
 Coppenhaver, D.H., see Hughes, T.K., 1  
 Cottagnoud, P., Neftel, K.A., Hany, M. and Zinkernagel, R.M.  
 Inhibition of HSV-1 and vaccinia virus replication by cephalosporin derivatives, 59

Dawson, M.I., see Burns, III, N.J., 89  
 De Clercq, E., see Burns, III, N.J., 89  
 De Clercq, E., see Ito, M., 289  
 DeLong, D.C., see Higgins, P.G., 141

Fanucchi, M.P., see Kong, X.-B., 153  
 Farrar, G.H., see Taylor, D.L., 11

Feldman, A., see Terry, B.J., 235  
 Fellows, L.E., see Taylor, D.L., 11  
 Fennie, E.H., Lie, Y.S., Low, M.-A.L., Gribling, P. and Anderson, K.P.  
 Reduced mortality in murine cytomegalovirus infected mice following prophylactic murine interferon- $\gamma$  treatment, 27  
 Field, A.K., see Terry, B.J., 235  
 Fohlman, J., see Ilbäck, N.-G., 129  
 Fox, J.J., see Kong, X.-B., 153  
 Frank, K.B., see Smee, D.F., 263  
 Friman, G., see Ilbäck, N.-G., 129

Gall, S.A., see Reichman, R.C., 41  
 Gorelik, E., see Li, X.Q., 179  
 Gribling, P., see Fennie, E.H., 27

Haffey, M.L., see Terry, B.J., 235  
 Hagen, M., see Terry, B.J., 235  
 Hany, M., see Cottagnoud, P., 59  
 Harrison, C.J., Jenski, L., Voychehovski, T. and Bernstein, D.I.  
 Modification of immunological responses and clinical disease during topical R-837 treatment of genital HSV-2 infection, 209  
 Harrison, C.J., see Myers, M.G., 83  
 Hasegawa, A., see Ikeda, S., 167  
 Hayden, F.G., Innes, Jr., D.J., Mills, S.E. and Levine, P.A.  
 Intranasal tolerance and histopathologic effects of a novel synthetic interferon, rIFN- $\alpha$ Con1, 225  
 Helbig, B., see Wutzler, P., 99  
 Higgins, P.G., Barrow, G.I., Al-Nakib, W., Tyrrell, D.A.J., DeLong, D.C. and Lenox-Smith, I.  
 Failure to demonstrate synergy between interferon- $\alpha$  and a synthetic antiviral, enviroxime, in rhinovirus infection in volunteers, 141  
 Hirabayashi, K., see Ito, M., 289  
 Ho, M., see Li, X.Q., 179  
 Homma, J.Y., see Ikeda, S., 167  
 Huffman, J.H., see Burns, III, N.J., 89  
 Huffman, J.H., see Sidwell, R.W., 193  
 Hughes, G., see Campos, M., 71  
 Hughes, T.K., Kaspar, T.A. and Coppenhaver, D.H.  
 Synergy of antiviral actions of TNF and IFN- $\gamma$ : evidence for a major role of TNF-induced IFN- $\beta$ , 1

Ikeda, S., Kumazawa, Y., Nishimura, C., Nakatsuka, M., Homma, J.Y., Kiso, M. and Hasegawa, A.  
Enhancement of nonspecific resistance to viral infection by chemically synthesized lipid A-subunit analogs with different backbone structures and acyl groups, 167

Ikeda, S., Sai, K., Nishimura, C. and Yamamoto, A.  
Antiherpes activity of the immunomodulator OK-432, a streptococcal preparation, in immunosuppressed mice (Short Communication), 299

Ilbäck, N.-G., Fohlman, J. and Friman, G.  
The anti-inflammatory effect of LS 2616 and poly I:C in coxsackievirus B3 induced murine myocarditis, 129

Innes, Jr., D.J., see Hayden, F.G., 225

Ito, M., Sato, A., Hirabayashi, K., Tanabe, F., S., Baba, M., De Clercq, E., Nakashima, H. and Yamamoto, N.  
Mechanism of inhibitory effect of glycyrrhizin on replication of human immunodeficiency virus (HIV), 289

Jeffries, D.J., see Taylor, D.L., 11

Jenski, L., see Harrison, C.J., 209

Kaspar, T.A., see Hughes, T.K., 1

Kende, M., see Burns, III, N.J., 89

Kini, G.D., see Smee, D.F., 253

Kiso, M., see Ikeda, S., 167

Kohl, S., see Bernstein, D.I., 279

Kong, X.-B., Scheck, A.C., Price, R.W., Vidal, P.M., Fanucchi, M.P., Watanabe, K.A., Fox, J.J. and Chou, T.-C.  
Incorporation and metabolism of 2'-fluoro-5-substituted arabinosyl pyrimidines and their selective inhibition of viral DNA synthesis in herpes simplex virus type 1 (HSV-1)-infected and mock-infected Vero cells, 153

Kucera, P., see Reichman, R.C., 41

Kumazawa, Y., see Ikeda, S., 167

Lawman, M.J.P., see Campos, M., 71

Lenox-Smith, I., see Higgins, P.G., 141

Levine, P.A., see Hayden, F.G., 225

Li, X.Q., Gorelik, E., Atchison, R.W., Ovejera, A. and Ho, M.  
A new *in vivo* anti-viral assay using microencapsulated infected cell cultures, 179

Lie, Y.S., see Fennie, E.H., 27

Loo, L.S., see Bernstein, D.I., 279

Low, M.-A.L., see Fennie, E.H., 27

Mazina, K.E., see Terry, B.J., 235

McKernan, P.A., see Smee, D.F., 263

Meerbach, A., see Wutzler, P., 99

Micha, J.P., see Reichman, R.C., 41

Mills, S.E., see Hayden, F.G., 225

Mobberley, M.A., see Taylor, D.L., 11

Mounts, P., see Reichman, R.C., 41

Meyers, M.G., Bernstein, D.I., Harrison, C.J. and Stanberry, L.R.  
Herpes simplex virus glycoprotein treatment of recurrent genital herpes reduces cervicovaginal virus shedding in guinea pigs, 83

Nakashima, H., see Ito, M., 289

Nakatsuka, N., see Ikeda, S., 167

Nash, R.J., see Taylor, D.L., 11

Neftel, K.A., see Cottagnoud, P., 59

Ngan, F., Chang, R.S., Tabba, H.D. and Smith, K.M.  
Isolation, purification and partial characterization of an active anti-HIV compound from the Chinese medicinal herb *Viola yedoensis*, 107

Nishimura, C., see Ikeda, S., 167

Nishimura, C., see Ikeda, S., 299

Orsi, N., see Conti, C., 117

Ovejera, A., see Li, X.Q., 179

Pifat, D.Y., see Sidwell, R.W., 193

Pradel, W., see Wutzler, P., 99

Price, R.W., see Kong, X.-B., 153

Ramasamy, K., see Smee, D.F., 263

Reichman, R.C., Micha, J.P., Weck, P.K., Bonnez, W., Wold, D., Whisnant, J.K., Mounts, P., Trofatter, K.D., Kucera, P. and Gall, S.A.  
Interferon alpha-1a (wellferon) for refractory genital warts: efficacy and tolerance of low dose systemic therapy, 41

Revankar, G.R., see Smee, D.F., 263

Robins, R.K., see Smee, D.F., 253

Robins, R.K., see Smee, D.F., 263

Ryder, T.A., see Taylor, D.L., 11

Sai, K., see Ikeda, S., 299

Sato, A., see Ito, M., 289

Scheck, A.C., see Kong, X.-B., 153

Shigeta, S., see Ito, M., 289

Sidwell, R.W., Huffman, J.H., Barnard, D.L. and Pifat, D.Y.  
Effects of ribamidine, a 3-carboxamidine derivative of ribavirin, on experimentally induced Phlebovirus infections, 193

Sidwell, R.W., see Burns, III, N.J., 89

Slusarchyk, W.A., see Terry, B.J., 235

Smee, D.F., Alaghmandan, H.A., Kini, G.D. and Robins, R.K.

Antiviral activity and mode of action of ribavirin 5'-sulfamate against Semliki Forest virus, 253

Smee, D.F., McKernan, P.A., Alaghmandan, H.A., Frank, K.B., Ramasamy, K., Revankar, G.R. and Robins, R.K.

Antiviral activities of 2'-deoxyribofuranosyl and arabinofuranosyl analogs of sangivamycin against retro- and DNA viruses, 263

Smith, K.M., see Ngan, F., 107

Stanberry, L.R., see Myers, M.G., 83

Stein, M.L., see Conti, C., 117

Tabba, H.D., see Ngan, F., 107

Tanabe, F., see Ito, M., 189

Taylor, D.L., Fellows, L.E., Farrar, G.H., Nash, R.J., Taylor-Robinson, D., Moerley, M.A., Ryder, T.A., Jeffries, D.J. and Tym, A.S.

Loss of cytomegalovirus infectivity after treatment with castanospermine or related plant alkaloids correlates with aberrant glycoprotein synthesis, 11

Taylor-Robinson, D., see Taylor, D.L., 11

Terry, B.J., Mazina, K.E., Tuomari, A.V., Hafeley, M.L., Hagen, M., Feldman, A., Slusarchyk, W.A., Young, M.G., Zahler, R. and Field, A.K.

Broad-spectrum antiviral activity of the acyclic guanosine phosphate (R,S)-HPMPG, 235

Trofatter, K.F., see Reichman, R.C., 41

Tuomari, A.V., see Terry, B.J., 235

Tym, A.S., see Taylor, D.L., 11

Tyrrell, D.A.J., see Higgins, P.G., 141

Ulbright, A., see Wutzler, P., 99

Vidal, P.M., see Kong, X.-B., 153

Voychehovski, T., see Harrison, C.J., 209

Watanabe, K.A., see Kong, X.-B., 153

Weck, P.K., see Reichman, R.C., 41

Whisnant, J.K., see Reichman, R.C., 41

Wold, D., see Reichman, R.C., 41

Wutzler, P., Helbig, B., Ulbricht, A., Meerbach, A. and Pradel, W.

Therapeutic effect of pyrophosphate analogues on cutaneous herpes simplex virus type 1 infection in guinea pigs, 99

Yamamoto, A., see Ikeda, S., 299

Yamamoto, N., see Ito, M., 289

Young, M.G., see Terry, B.J., 235

Zahlerr, R., see Terry, B.J., 235

Zinkernagel, R.M., see Cottagnoud, P., 59

